Homing in on the right Alzheimer’s patients for anti-amyloid therapy

The full data from Eli Lilly’s TRAILBLAZER ALZ2 trial keep donanemab on an apparently clear path to FDA approval for Alzheimer’s disease, but raise the question of whether the agency will require testing for tau PET status on the label — an outcome that would reduce donanemab’s total addressable market relative to that of Leqembi, its major competitor, though uptake of both therapies will be slow in all events.  

At the 2023 Alzheimer's Association International Conference Monday, Eli Lilly and Co. (NYSE:LLY) provided some of the most compelling clinical data to date on a long-standing hypothesis in the amyloid field: that the drug class will be most effective in the earliest stages of disease. ...